Rational Antipsychotic Choice: Weighing the Risk of Tardive Dyskinesia and Metabolic Syndrome

REFERENCES

• Hansell N. Services for schizophrenics: a lifelong approach to treatment. Hosp Community Psychiatry 1978;29:105–9.
   PubMedGoogle Scholar
• Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255–62.
   PubMed Web of Science ®Google Scholar
• Moore TA, Buchanan RW, Buckley PF, The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751–62.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71–93.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 suppl):1–56.
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23.
   PubMed Web of Science ®Google Scholar
• Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010;55:117–25.
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079–87.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Davis VG, Goff DC, Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008;101:273–86.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19:1–93.
   PubMed Web of Science ®Google Scholar
• Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010;10:209–16.
   PubMed Web of Science ®Google Scholar
• Domino ME, Swartz MetS. Who are the new users of antipsychotic medications? Psychiatr Serv 2008;59:507–14.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesisa: is risk declining with modern antipsychotics? Mov Disord 2006;21:589–98.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703–14.
   PubMed Web of Science ®Google Scholar
• Cavallaro R, Regazzetti MG, Mundo E, Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology 1993;8:233–9.
   Google Scholar
• Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997;171:265–8.
   PubMed Web of Science ®Google Scholar
• Lohr JM. Commentary: is tardive dyskinesia disappearing? In: Factor SA, Lang AE, Weiner WJ, Lang AE, eds. Drug induced movements disorders. Malden, MA: Futura-Blackwell, 2004.
   Google Scholar
• Morgenstern H, Glazer W. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993;50:723–33.
   PubMed Web of Science ®Google Scholar
• Jeste D. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004;65:21–4.
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupta DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480–91.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68:20–7.
   PubMed Web of Science ®Google Scholar
• Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753–60.
   PubMed Web of Science ®Google Scholar
• Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry 2004;184:76–9.
   Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:13–8.
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059–62.
   PubMed Web of Science ®Google Scholar
• Parsons B, Allison DB, Loebel A, Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009;110:103–10.
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–14.
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–9.
   PubMed Web of Science ®Google Scholar
• De Hert M, Peuskens B, van Winkel R, Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res 2006;88:222–6.
   PubMed Web of Science ®Google Scholar
• Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496–502.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Dunn G, Kaminsky MJ, Breakey WR. Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics 2002;43:24–30.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66: 51–7.
   PubMed Web of Science ®Google Scholar
• Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain. Drug Saf 2006;29:303–19.
   PubMed Web of Science ®Google Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189:259–66.
   PubMed Web of Science ®Google Scholar
• Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007;93: 90–8.
   PubMed Web of Science ®Google Scholar
• Brecher M, Leong RW, Stening G, Osterling-Koskinen L, Jones AM. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007;68:597–603.
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Sweers K, Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008;101:295–303.
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2000;4161: 414–25.
   Google Scholar
• Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 2007;68:1901–6.
   PubMed Web of Science ®Google Scholar
• Miller DD, Caroff SN, Davis SM, Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279–88.
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Anconetani B, The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;50: 517–27.
   PubMed Web of Science ®Google Scholar
• Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F. Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 2007;82:509–24.
   PubMed Web of Science ®Google Scholar
• Ravikiran M, Bhansali A, Ravikumar P, Prevalence and risk factors of metabolic syndrome among Asian Indians: a community survey. Diabetes Res Clin Pract 2010;89:181–8.
   PubMed Web of Science ®Google Scholar
• Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004;65:16–20.
   PubMed Web of Science ®Google Scholar
• Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:857–64.
   PubMed Web of Science ®Google Scholar
• Dean CE, Thuras PD. Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br J Psychiatry 2009;194:360–4.
   PubMed Web of Science ®Google Scholar
• Kennedy J, Tien YY, Cohen LJ, The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey. Clin Ther 2009;31:2931–9.
   Google Scholar
• Aparasu RR, Jano E, Johnson ML, Chen H. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am J Geriatr Pharmacother 2008;6:198–204.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs 2009;23:171–80.
   PubMed Web of Science ®Google Scholar